A complication of fiberoptic intubation.

R. Kadish,A. Gottschalk

DOI: https://doi.org/10.1213/00000539-199306000-00043

Abstract:

What problem does this paper attempt to address?

Digital obstructive arterial disease can be detected by laser Doppler measurements with high sensitivity and specificity.

G. Mahé,D. Liedl,C. Mccarter,R. Shepherd,P. Gloviczki,I. McPhail,T. Rooke,P. Wennberg

DOI: https://doi.org/10.1016/j.jvs.2013.10.076

IF: 4.86

2014-04-01

Journal of Vascular Surgery

Abstract:
RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system

Huyen Le,Ru Chen,Stephen Harris,Hong Fang,Beverly Lyn-Cook,Huixiao Hong,Weigong Ge,Paul Rogers,Weida Tong,Wen Zou

DOI: https://doi.org/10.3389/fbinf.2023.1328613

2024-01-01

Frontiers in Bioinformatics

Abstract:Numerous studies have been conducted on the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) database to assess post-marketing reporting rates for drug safety review and risk assessment. However, the drug names in the adverse event (AE) reports from FAERS were heterogeneous due to a lack of uniformity of information submitted mandatorily by pharmaceutical companies and voluntarily by patients, healthcare professionals, and the public. Studies using FAERS and other spontaneous reporting AEs database without drug name normalization may encounter incomplete collection of AE reports from non-standard drug names and the accuracies of the results might be impacted. In this study, we demonstrated applicability of RxNorm, developed by the National Library of Medicine, for drug name normalization in FAERS. Using prescription opioids as a case study, we used RxNorm application program interface (API) to map all FDA-approved prescription opioids described in FAERS AE reports to their equivalent RxNorm Concept Unique Identifiers (RxCUIs) and RxNorm names. The different names of the opioids were then extracted, and their usage frequencies were calculated in collection of more than 14.9 million AE reports for 13 FDA-approved prescription opioid classes, reported over 17 years. The results showed that a significant number of different names were consistently used for opioids in FAERS reports, with 2,086 different names (out of 7,892) used at least three times and 842 different names used at least ten times for each of the 92 RxNorm names of FDA-approved opioids. Our method of using RxNorm API mapping was confirmed to be efficient and accurate and capable of reducing the heterogeneity of prescription opioid names significantly in the AE reports in FAERS; meanwhile, it is expected to have a broad application to different sets of drug names from any database where drug names are diverse and unnormalized. It is expected to be able to automatically standardize and link different representations of the same drugs to build an intact and high-quality database for diverse research, particularly postmarketing data analysis in pharmacovigilance initiatives.
Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)

Stefania Chiappini,Rachel Vickers-Smith,Amira Guirguis,John M. Corkery,Giovanni Martinotti,Daniel R. Harris,Fabrizio Schifano

DOI: https://doi.org/10.3390/ph15060675

IF: 4.6

2022-05-27

Pharmaceuticals

Abstract:In the past twenty years, the consumption of opioid medications has reached significant proportions, leading to a rise in drug misuse and abuse and increased opioid dependence and related fatalities. Thus, the purpose of this study was to determine whether there are pharmacovigilance signals of abuse, misuse, and dependence and their nature for the following prescription opioids: codeine, dihydrocodeine, fentanyl, oxycodone, pentazocine, and tramadol. Both the pharmacovigilance datasets EudraVigilance (EV) and the FDA Adverse Events Reporting System (FAERS) were analyzed to identify and describe possible misuse-/abuse-/dependence-related issues. A descriptive analysis of the selected Adverse Drug Reactions (ADRs) was performed, and pharmacovigilance signal measures (i.e., reporting odds ratio, proportional reporting ratio, information component, and empirical Bayesian geometric mean) were computed for preferred terms (PTs) of abuse, misuse, dependence, and withdrawal, as well as PTs eventually related to them (e.g., aggression). From 2003 to 2018, there was an increase in ADR reports for the selected opioids in both datasets. Overall, 16,506 and 130,293 individual ADRs for the selected opioids were submitted to EV and FAERS, respectively. Compared with other opioids, abuse concerns were mostly recorded in relation to fentanyl and oxycodone, while tramadol and oxycodone were more strongly associated with drug dependence and withdrawal. Benzodiazepines, antidepressants, other opioids, antihistamines, recreational drugs (e.g., cocaine and alcohol), and several new psychoactive substances, including mitragynine and cathinones, were the most commonly reported concomitant drugs. ADRs reports in pharmacovigilance databases confirmed the availability of data on the abuse and dependence of prescription opioids and should be considered a resource for monitoring and preventing such issues. Psychiatrists and clinicians prescribing opioids should be aware of their misuse and dependence liability and effects that may accompany their use, especially together with concomitant drugs.

pharmacology & pharmacy,chemistry, medicinal
Patterns of Routes of Administration and Drug Tampering for Nonmedical Opioid Consumption: Data Mining and Content Analysis of Reddit Discussions

Duilio Balsamo,Paolo Bajardi,Alberto Salomone,Rossano Schifanella

DOI: https://doi.org/10.48550/arXiv.2102.11235

2021-02-22

Computers and Society

Abstract:The complex unfolding of the US opioid epidemic in the last 20 years has been the subject of a large body of medical and pharmacological research, and it has sparked a multidisciplinary discussion on how to implement interventions and policies to effectively control its impact on public health. This study leverages Reddit as the primary data source to investigate the opioid crisis. We aimed to find a large cohort of Reddit users interested in discussing the use of opioids, trace the temporal evolution of their interest, and extensively characterize patterns of the nonmedical consumption of opioids, with a focus on routes of administration and drug tampering. We used a semiautomatic information retrieval algorithm to identify subreddits discussing nonmedical opioid consumption, finding over 86,000 Reddit users potentially involved in firsthand opioid usage. We developed a methodology based on word embedding to select alternative colloquial and nonmedical terms referring to opioid substances, routes of administration, and drug-tampering methods. We modeled the preferences of adoption of substances and routes of administration, estimating their prevalence and temporal unfolding, observing relevant trends such as the surge in synthetic opioids like fentanyl and an increasing interest in rectal administration. Ultimately, through the evaluation of odds ratios based on co-mentions, we measured the strength of association between opioid substances, routes of administration, and drug tampering, finding evidence of understudied abusive behaviors like chewing fentanyl patches and dissolving buprenorphine sublingually. We believe that our approach may provide a novel perspective for a more comprehensive understanding of nonmedical abuse of opioids substances and inform the prevention, treatment, and control of the public health effects.
Impact of COVID-19 Pandemic on Emergency Department Visits for Opioid Use Disorder Across University of California Health Centers

Matthew Heshmatipour,Ding Quan Ng,Emily Yi-Wen Truong,Jianwei Zheng,Alexandre Chan,Yun Wang

DOI: https://doi.org/10.5811/westjem.18468

2024-10-03

Western Journal of Emergency Medicine

Abstract:Introduction: Coronavirus 2019 (COVID-19) has had a devastating impact on mental health and access to addiction treatment in the United States, including in California, which resulted in the highest rates of emergency department visits (ED) for opioid poisoning in 2020. As California slowly returns to pre-pandemic normalcy, it remains uncertain whether the rates of opioid-related events have slowed down over time. We hypothesized that the number of opioid-related ED visits were exacerbated after the period of the COVID-19 pandemic and continue at a high rate in the present. Methods: In this analysis we searched the University of California (UC) Health Data Warehouse—a database of electronic health records from six UC health centers—for opioid-related ED visits, identifiying using the following International Classification of Diseases, 10th Ed, Clinical Modification codes: F11 codes, and T40.0*, T40.1*, T40.2*, T40.3*, T40.4*, T40.6*. Opioid overdose-associated visits were classified by types of opioids involved: heroin (T40.1*); prescription opioids (T40.2* or T40.3*); and synthetic opioids (T40.4*). We performed interrupted time analysis to estimate the immediate (level) change and change-in-time trend (trend change), from before (January 2018–October 2019) and during the pandemic (April 2020–December 2022). Monthly visit rates were evaluated with negative binomial regression adjusted for first-order autoregression and using all-cause ED counts as the offset. We present effect sizes as rate ratios (RR) and 95% confidence intervals (CI), tested at α = .05. Results: Before COVID-19, a steadily increasing trend in ED visit rates was observed for all outcomes (P < 0.05) except synthetic opioids. Total opioid-related ED visit rates increased by 15% (RR 1.15, 95%CI 1.02–1.29, P = 0.20) immediately after March 2020 before decreasing by 0.5% every month, albeit without statistical significance (RR .995, 95% CI .991–1.00, P = 0.06). Similar trends were observed with prescription opioid overdoses, with a step increase of 44% (RR 1.44, 95% CI 1.10–1.89, P = .008) before plateauing after March 2020 (RR 1.01, 95% CI .998–1.02, P = 0.12). After March 2020, ED visit rates for synthetic opioid overdoses were increasing steadily by 4% every month (RR 1.04, 95% CI 1.02–1.06, P = .001), unlike with heroin, which was observed with an 8% monthly reduction (RR .92, 95% CI .90–.93, P < .001). No immediate increase in visit rates was observed for either opioid. Conclusion: While opioid-related ED admissions among the UC health centers showed an overall decrease, prescription and synthetic opioid overdoses remained significantly higher than pre-pandemic trends as of December 2022. A multilevel approach to improve awareness of new opioid health policies could ameliorate these alarming rises in the post-pandemic era.

emergency medicine
EPR studies of the cytochrome b-c 1 segment of the mitochondrial electron transfer system.

N. Orme-Johnson,R. E. Hansen,H. Beinert

DOI: https://doi.org/10.1016/0006-291X(71)90419-0

1971-11-19

Abstract:
Serious Medical Outcomes due to Single Substance Opioid Exposures

Aaron Frey,Christopher Holsteg,Kawai Tanabe,Moira Smith,Saumitra Rege,Will Goodrich

DOI: https://doi.org/10.5811/westjem.58900

2024-01-24

Western Journal of Emergency Medicine

Abstract:Objectives: The present study sought to evaluate the recent trends in the severe outcomes to single substance opioid exposures (SSO) reported to the U.S. poison centers (PCs).Background: Misuse of prescription opioids continues to be a significant public health crisis globally. According to the Centers for Disease Control and Prevention (CDC), there were more than 72,000 overdose deaths in the United States (U.S.), with 49,068 involving an opioid.Methods: The NPDS was queried for single substance opioid exposures that were reported to the U.S. PCs from 2011 to 2011. Cases with severe outcomes (SO) were defined as exposures that resulted in either a death or major clinical outcomes. We identified and descriptively assessed the relevant demographic and clinical characteristics. Poisson regression models were used to evaluate the trends in the number and rates (per 100,000 human exposures) of single substance opioid exposures resulting in SO. Percent changes from the first year of the study (2011) were reported with the corresponding 95% confidence intervals (95% CI). Logistic regression was utilized to study the risk markers of severe outcomes.Results: Overall there were 308,202 single substance opioid-related cases reported to the U.S. PCs during the study period. The proportion of cases from ACH increased during the study period (32.9% vs 48.9%). Among cases with severe outcomes, ages between 20 and 29 years (27.9%) constituted the most common age group. Males accounted for 57.4% cases. Most exposures with SO occurred in a residence (83.7%). Hydrocodone (25.6%) was the most common opioid reported in cases followed by oxycodone (18.7%). Intentional abuse (48.4% vs 12.7%) and suspected suicides (24.7% vs 12.9%) were more common in exposures with SO compared to those without SO. Similarly, non-oral routes of administration were more common in exposures with SO (40.9% vs 8.1%). The rate of exposures with SO increased by 71.3% (95% CI: 63.4%, 79.9%, p<0.001). The risk of SO with single substance opioid-related exposures was the highest in cases between 50 and 59 years of age (Ref: 20 – 29 years) (AOR: 1.61, 95% CI: 1.52 – 1.71). Males were 16% more likely than females to have serious outcomes (AOR: 1.16, 95% CI: 1.12 – 1.20). The risk for severe outcomes with single substance opioid exposures was significantly elevated in hydrocodone (AOR: 2.43, 95% CI: 2.30 – 2.58), oxycodone (AOR: 1.64, 95% CI: 1.55 – 1.73) and tramadol (AOR: 1.80, 95% CI: 1.69 – 1.92) exposures. Other Important predictors of a single substance opioid-related SO were suspected suicides (Ref: Unintentional exposure) (AOR: 3.82, 95% CI: 3.67 – 4.09), non-oral routes of administration (Ref: Ingestion) (AOR: 2.94, 95% CI: 2.80 – 3.00) and exposure in the west census region of the U.S. (Ref: Northeast region) (AOR: 1.21, 95% CI: 1.16 – 1.28).Conclusion: The number of single substance opioid exposures cases handled by the PCs decreased, but those with severe outcomes increased significantly. Hydrocodone and oxycodone were the most common opioid reported for the sample. Personalized evidence-based strategies, population level interventions, creation of protective environments, and better screening of patients are some key measure to limit this trend.

emergency medicine
Network Analysis and Visualisation of Opioid Prescribing Data

Xuelei Hu,Marcus Gallagher,William Loveday,Abhilash Dev,Jason P Connor

DOI: https://doi.org/10.1109/JBHI.2019.2939028

Abstract:In many countries around the world (including Australia), the prescribing of opioid analgesic drugs is an increasing trend associated with significant increases in drug-related patient harm such as abuse, overdose, and death. In Australia, the Medicines Regulation and Quality Unit within Queensland Health maintains a database recording opioid analgesic drug prescriptions dispensed across the State (population 4.703 million). In this work, we propose the use of network visualisation and analysis as a tool for improved understanding of these data. Prescribing data for Fentanyl patches, a strong opioid with high potential for misuse and subsequent harm, across Queensland, Australia from 2011 to 2018 is analysed as an example of using network analysis, where prescribing patterns are viewed as a dynamic, bipartite graph of the interactions between patients and prescribers over time. The technique provides a global view of a large state-wide prescribing dataset, including the distribution of subgraph structures present. Local analysis is also carried out to demonstrate the clinical utility of the technique, including the dynamics of the graph structure over time. A variety of network statistics that measure network structural and dynamic properties are presented to reveal the characteristics and trends of drug seeking and prescribing behaviours. This approach has been recognised by healthcare professionals at Queensland Health as leading to new and useful insights on the relationship between patients and prescribers and supporting their advisory role to reduce patient harm from inappropriate use of prescription drugs.
Reframing the Prevention Strategies of the Opioid Crisis: Focusing on Prescription Opioids, Fentanyl, and Heroin Epidemic

Laxmaiah Manchikanti,Jaya Sanapati,Ramsin M Benyamin,Sairam Atluri,Alan D Kaye,Joshua A Hirsch

IF: 4.396

Pain Physician

Abstract:The opioid epidemic has been called the "most consequential preventable public health problem in the United States." Though there is wide recognition of the role of prescription opioids in the epidemic, evidence has shown that heroin and synthetic opioids contribute to the majority of opioid overdose deaths. It is essential to reframe the preventive strategies in place against the opioid crisis with attention to factors surrounding the illicit use of fentanyl and heroin. Data on opioid overdose deaths shows 42,000 deaths in 2016. Of these, synthetic opioids other than methadone were responsible for over 20,000, heroin for over 15,000, and natural and semi-synthetic opioids other than methadone responsible for over 14,000. Fentanyl deaths increased 520% from 2009 to 2016 (increased by 87.7% annually between 2013 and 2016), and heroin deaths increased 533% from 2000 to 2016. Prescription opioid deaths increased by 18% overall between 2009 and 2016. The Drug Enforcement Administration (DEA) mandated reductions in opioid production by 25% in 2017 and 20% in 2018. The number of prescriptions for opioids declined significantly from 252 million in 2013 to 196 million in 2017 (9% annual decline over this period), falling below the number of prescriptions in 2006. In addition, data from 2017 shows significant reductions in the milligram equivalence of morphine by 12.2% and in the number of patients receiving high dose opioids by 16.1%. This manuscript describes the escalation of opioid use in the United States, discussing the roles played by drug manufacturers and distributors, liberalization by the DEA, the Food and Drug Administration (FDA), licensure boards and legislatures, poor science, and misuse of evidence-based medicine. Moreover, we describe how the influence of pharma, improper advocacy by physician groups, and the promotion of literature considered peer-reviewed led to the explosive use of illicit drugs arising from the issues surrounding prescription opioids.This manuscript describes a 3-tier approach presented to Congress. Tier 1 includes an aggressive education campaign geared toward the public, physicians, and patients. Tier 2 includes facilitation of easier access to non-opioid techniques and the establishment of a National All Schedules Prescription Electronic Reporting Act (NASPER). Finally, Tier 3 focuses on making buprenorphine more available for chronic pain management as well as for medication-assisted treatment. Key words: Opioid epidemic, fentanyl and heroin epidemic, prescription opioids, National All Schedules Prescription Electronic Reporting Act (NASPER), Prescription Drug Monitoring Programs (PDMPs).
Large-scale Analysis of Opioid Poisoning Related Hospital Visits in New York State

Xin Chen,Yu Wang,Xiaxia Yu,Elinor Schoenfeld,Mary Saltz,Joel Saltz,Fusheng Wang

DOI: https://doi.org/10.48550/arXiv.1711.05779

2017-11-15

Populations and Evolution

Abstract:Opioid related deaths are increasing dramatically in recent years, and opioid epidemic is worsening in the United States. Combating opioid epidemic becomes a high priority for both the U.S. government and local governments such as New York State. Analyzing patient level opioid related hospital visits provides a data driven approach to discover both spatial and temporal patterns and identity potential causes of opioid related deaths, which provides essential knowledge for governments on decision making. In this paper, we analyzed opioid poisoning related hospital visits using New York State SPARCS data, which provides diagnoses of patients in hospital visits. We identified all patients with primary diagnosis as opioid poisoning from 2010-2014 for our main studies, and from 2003-2014 for temporal trend studies. We performed demographical based studies, and summarized the historical trends of opioid poisoning. We used frequent item mining to find co-occurrences of diagnoses for possible causes of poisoning or effects from poisoning. We provided zip code level spatial analysis to detect local spatial clusters, and studied potential correlations between opioid poisoning and demographic and social-economic factors.
Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review

Patil Armenian,Kathy T. Vo,Jill Barr-Walker,Kara L. Lynch

DOI: https://doi.org/10.1016/j.neuropharm.2017.10.016

IF: 5.273

2018-05-01

Neuropharmacology

Abstract:Deaths from opioid use are increasing in the US, with a growing proportion due to synthetic opioids. Until 2013, sporadic outbreaks of fentanyl and fentanyl analogs contaminating the heroin supply caused some deaths in heroin users. Since then, fentanyl has caused deaths in every state and fentanyl and its analogs have completely infiltrated the North American heroin supply. In 2014, the first illicit pills containing fentanyl, fentanyl analogs, and other novel synthetic opioids such as U-47700 were detected. These pills, which look like known opioids or benzodiazepines, have introduced synthetic opioids to more unsuspecting customers. As soon as these drugs are regulated by various countries, new compounds quickly appear on the market, making detection difficult and the number of cases likely underreported. Standard targeted analytical techniques such as GC-MS (gas chromatography mass spectrometry) and LC-MS/MS (liquid chromatography tandem mass spectrometry) can detect these drugs, but novel compound identification is aided by nontargeted testing with LC-HRMS (liquid chromatography high resolution mass spectrometry). Fentanyl, fentanyl analogs and other novel synthetic opioids are all full agonists of varying potencies at the μ-opioid receptor, leading to typical clinical effects of miosis and respiratory and central nervous system depression. Due to their high affinity for μ-opioid receptors, larger doses of naloxone are required to reverse the effects than are commonly used. Synthetic opioids are an increasingly major public health threat requiring vigilance from multiple fields including law enforcement, government agencies, clinical chemists, pharmacists, and physicians, to name a few, in order to stem its tide. This article is part of the Special Issue entitled 'Designer Drugs and Legal Highs.'

pharmacology & pharmacy,neurosciences
Examining Racial/Ethnic Differences in Patterns of Opioid Prescribing: Results from an Urban Safety-Net Healthcare System

Michael William Flores,Amanda Sharp,Frederick Lu,Benjamin Lê Cook

DOI: https://doi.org/10.1007/s40615-023-01555-z

2023-03-09

Journal of Racial and Ethnic Health Disparities

Abstract:Prescription opioids still account for a large proportion of overdose deaths and contribute to opioid use dependence (OUD). Studies earlier in the epidemic suggest clinicians were less likely to prescribe opioids to racial/ethnic minorities. As OUD-related deaths have increased disproportionately amongst minority populations, it is essential to understand racial/ethnic differences in opioid prescribing patterns to inform culturally sensitive mitigation efforts. The purpose of this study is to estimate racial/ethnic differences in opioid medication use among patients prescribed opioids. Using electronic health records and a retrospective cohort study design, we estimated multivariable hazard models and generalized linear models, assessing racial/ethnic differences in OUD diagnosis, number of opioid prescriptions, receiving only one opioid prescription, and receiving ≥18 opioid prescriptions. Study population (N=22,201) consisted of adult patients (≥18years), with ≥3 primary care visits (ensuring healthcare system linkage), ≥1 opioid prescription, who did not have an OUD diagnoses prior to the first opioid prescription during the 32-month study period. Relative to racial/ethnic minority patients, White patients, in both unadjusted and adjusted analyses, had a greater number of opioid prescriptions filled, a higher proportion received ≥18 opioid prescriptions, and a greater hazard of having an OUD diagnosis subsequent to receiving an opioid prescription (all groups p<0.001). Although opioid prescribing rates have declined nationally, our findings suggest White patients still experience a high volume of opioid prescriptions and greater risk of OUD diagnosis. Racial/ethnic minorities are less likely to receive follow-up pain medications, which may signal low care quality. Identifying provider bias in pain management of racial/ethnic minorities could inform interventions seeking balance between adequate pain treatment and risk of opioid misuse/abuse.

public, environmental & occupational health
Evidence for the synthesis of thymosin alpha 1 by calf thymocytes and the production of this peptide by natural processing.

M. Freire,M. Rey-Méndez,J. Gómez-Márquez,P. Arias

IF: 4.114

Archives of Biochemistry and Biophysics

Abstract:Thymus and thymocytes from calf were extracted under isotonic conditions in the presence of protease inhibitors or under severe denaturing conditions (after quick freezing and thawing in boiling 0.1 M NaCl). The extracts, as well as the medium in which the thymocytes were obtained from thymus fragments (thymocyte supernatants), were size-fractionated by ultrafiltration. As in whole thymus isotonic extracts, thymosin alpha 1 [A. L. Goldstein, T. L. K. Low, M. McAdoo, J. McClure, G. B. Thurman, J. Rossio, C-Y. Lai, D. Chang, S-S. Wang, C. Harvey, A. H. Ramel, and J. Meienhofer (1977) Proc. Natl. Acad. Sci. USA 74, 725-729] was contained in isotonic extracts from thymocytes and also in thymocyte supernatants, as determined by isoelectric focusing and reverse-phase HPLC analysis. The extraction under denaturing conditions mainly yielded products with molecular masses over 50,000, showing very similar isoelectric focusing patterns in both thymocytes and whole thymus extracts. As deduced by isoelectric focusing analysis of diverse size-fractionated products, a strong association capacity seems to be responsible for an apparently high molecular mass of the components of these extracts. According to the pI, two of these components were prothymosin alpha [A. A. Haritos, G. J. Goodall, and B. L. Horecker (1984) Proc. Natl. Acad. Sci. USA 81, 1008-1011] and thymosin alpha 1. Prothymosin alpha was not detected in any isotonic extracts or thymocyte supernatants. These data suggest that calf thymocytes are capable of producing thymosin alpha 1, which would arise by natural processing of its precursor.
Progress, Challenges, and Prospects of Research on the Effect of Gene Polymorphisms on Adverse Reactions to Opioids

Jinsong Zhao,Shihong Cai,Long Zhang,Yuefeng Rao,Xianhui Kang,Zhiying Feng

DOI: https://doi.org/10.1007/s40122-022-00374-0

IF: 3.96

2022-04-16

Pain and Therapy

Abstract:The abuse of opioids has become one of the most serious concerns in the world. Opioid use can cause serious adverse reactions, including respiratory depression, postoperative nausea and vomiting, itching, and even death. These adverse reactions are also important complications of clinical application of opioid drugs that may affect patient safety and recovery. Due to the fear of adverse reactions of opioids, clinicians often do not dare to use opioids in an adequate or appropriate amount, thus affecting the clinical medication strategy and the quality of treatment for patients. The prediction of adverse reactions to opioids is one of the most concerned problems in clinical practice. At present, the correlation between gene polymorphism and the efficacy of opiates has been widely studied and preliminarily confirmed, but the research on the effect of gene polymorphism on the adverse reactions of opiates is relatively limited. Existing studies have made encouraging progress in predicting the incidence and severity of adverse opioid reactions and clinical management by using genetic testing, but most of these studies are single-center, small-sample clinical studies or animal experiments, which have strong limitations. When the same receptor or enzyme is studied by different experimental methods, different or even opposite conclusions can be drawn. These phenomena indicate that the correlation between gene polymorphism and adverse opioid reaction still needs further research and demonstration. At present, it is still too early to use genetic testing to predict opioid adverse reactions in clinic. In this paper, the correlation between gene polymorphism and adverse opioid reactions and a small number of clinical applications were reviewed in terms of pharmacokinetics and pharmacodynamics, in order to provide some suggestions for future research and clinical drug decision making.

clinical neurology
Monitoring the opioid epidemic via social media discussions

Adam Lavertu,Tymor Carpenter Hamamsy,Russ B. Altman,Johannes Eichstaedt,Delaney Smith

DOI: https://doi.org/10.1101/2021.04.01.21254815

2024-11-20

Abstract:Opioid-involved overdose deaths have risen significantly since 1999 with over 80,000 deaths annually since 2021, primarily driven by synthetic opioids, like fentanyl. Responding to the rapidly changing opioid crisis requires reliable and timely information. One possible source of such data is the social media platforms with billions of user-generated posts, a fraction of which are about drug use. We therefore assessed the utility of Reddit data for surveillance of the opioid epidemic, covering prescription, heroin, and synthetic drugs (as of September 2024, up-to-date Reddit data was still accessible on the open web). Specifically, we built a natural language processing pipeline to identify opioid-related comments and created a cohort of 1,689,039 geolocated Reddit users, each assigned to a state. We followed these users from 2010 through 2022, measured their opioid-related posting activity over time, and compared this posting activity against CDC overdose and National Forensic Laboratory Information System (NFLIS) drug report rates. To simulate the real-world prediction of synthetic drug overdose rates, we added near real-time Reddit data to a model relying on CDC mortality data with a typical 6-month reporting lag and found that Reddit data significantly improved prediction accuracy. We observed drastic, largely unpredictable changes in both Reddit and overdose patterns during the COVID-19 pandemic. Reddit discussions covered a wide variety of drug types that are currently missed by official reporting. This work suggests that social media can help identify and monitor known and emerging drug epidemics and that this data is a public health "common good" to which researchers should continue to have access.
Evolution of an epidemic: Understanding the opioid epidemic in the United States and the impact of the COVID-19 pandemic on opioid-related mortality

Rachel Laing,Christl A Donnelly

DOI: https://doi.org/10.1371/journal.pone.0306395

IF: 3.7

2024-07-09

PLoS ONE

Abstract:We conduct this research with a two-fold aim: providing a quantitative analysis of the opioid epidemic in the United States (U.S.), and exploring the impact of the COVID-19 pandemic on opioid-related mortality. The duration and persistence of the opioid epidemic lends itself to the need for an overarching analysis with extensive scope. Additionally, studying the ramifications of these concurrent severe public health crises is vital for informing policies to avoid preventable mortality. Using data from CDC WONDER, we consider opioid-related deaths grouped by Census Region spanning January 1999 to October 2022 inclusive, and later add on a demographic component with gender-stratification. Through the lens of key events in the opioid epidemic, we build an interrupted time series model to reveal statistically significant drivers of opioid-related mortality. We then employ a counterfactual to approximate trends in the absence of COVID-19, and estimate excess opioid-related deaths (defined as observed opioid-related deaths minus projected opioid-related deaths) associated with the pandemic. According to our model, the proliferation of fentanyl contributed to sustained increases in opioid-related death rates across three of the four U.S. census regions, corroborating existing knowledge in the field. Critically, each region has an immediate increase to its opioid-related monthly death rate of at least 0.31 deaths per 100,000 persons at the start of the pandemic, highlighting the nationwide knock-on effects of COVID-19. There are consistent positive deviations from the expected monthly opioid-related death rate and a sizable burden from cumulative excess opioid-related deaths, surpassing 60,000 additional deaths nationally from March 2020 to October 2022, ∼70% of which were male. These results suggest that robust, multi-faceted measures are even more important in light of the COVID-19 pandemic to prevent overdoses and educate users on the risks associated with potent synthetic opioids such as fentanyl.
Saving the planet, one handset at a time: designing low-power, low-bandwidth GPUs

T. Olson

DOI: https://doi.org/10.1145/2341910.2341912

2012-08-05

Abstract:GPUs for mobile devices have to deliver ever-increasing performance and capability while living within strict power and memory bandwidth limits. In this talk we'll explore how these limits influence the design of mobile GPUs, and how applications can exploit GPU features to achieve the best power efficiency and performance, using ARM's Mali#8482; GPU family as a case study.
Efficacy of opioids for traumatic pain in the emergency department: a systematic review and Bayesian network meta-analysis

Yawen Fu,Qiang Liu,Hu Nie

DOI: https://doi.org/10.3389/fphar.2023.1209131

IF: 5.6

2023-07-28

Frontiers in Pharmacology

Abstract:Aim: To systematically assess and rank the efficacy of opioid medications for traumatic pain in the emergency department in terms of pain relief, adverse events and rescue analgesia. Methods: Four databases were systematically searched until 26 September 2022: PubMed, Embase, Cochrane Library, and Web of Science. Outcomes were pain relief, adverse events (dizziness, hypotension, pruritus, sedation), and rescue analgesia. For each outcome, network plots were drawn to exhibit direct and indirect comparisons, and rank probabilities were utilized to rank the efficacy of different opioids. Results: Twenty studies of 3,040 patients were eligible for this network meta-analysis. According to the rank probabilities, the top three analgesic medications for pain relief may be sufentanil (78.29% probability of ranking first), buprenorphine (48.54% probability of ranking second) and fentanyl (53.25% probability of ranking third); buprenorphine (31.20%), fentanyl (20.14%) and sufentanil (21.55%) were least likely to cause dizziness; the top three analgesic medications which were least likely to cause hypotension were buprenorphine (81.64%), morphine (45.02%) and sufentanil (17.27%); butorphanol (40.56%), morphine (41.11%) and fentanyl (14.63%) were least likely to cause pruritus; the top three medications which were least likely to cause sedation were hydrocodone + acetaminophen (97.92%), morphine (61.85%) and butorphanol (55.24%); patients who received oxycodone (83.64%), butorphanol (38.31%) and fentanyl (25.91%) were least likely to need rescue analgesia in sequence. Conclusion: Sufentanil, buprenorphine and fentanyl may be superior to other opioid medications in terms of pain relief and the incidence of dizziness, hypotension and pruritus, which might be selected as opioid analgesics for traumatic pain in the emergency setting.

pharmacology & pharmacy
Opioid-related clinical outcomes and associated healthcare costs following abuse/misuse of oxycodone formulations: A HEOR analysis from real-world data

Jody L Green,Taryn Dailey-Govoni,Suzanne K Vosburg

DOI: https://doi.org/10.5055/jom.0878

Abstract:Objective: The United States (US) opioid epidemic is a continued burden on the healthcare system and on the lives of individuals affected by the consequences of opioid abuse/misuse. The objective of this study was to use real-world data from intentional abuse/misuse exposures managed by US poison centers to compare clinical outcomes and quantify healthcare costs among three study cohorts: -exposures that involved Xtampza ER®, other oxycodone extended-release (ER), and oxycodone immediate-release (IR). Study design: A real-world, observational study. Main outcome measures: Descriptive statistics were used to describe patient and exposure characteristics. Drug utilization-adjusted rates of intentional abuse/misuse and clinical outcomes were used to determine relative risk. Healthcare cost estimates were calculated by extrapolating average charge per opioid-related disorder emergency department (ED) visit and per inpatient stay based upon case disposition rates, adjusted for population and drug utilization. Results: Compared to Xtampza ER, exposures that involved other oxycodone ER were 7.4 times more likely to be intentional abuse/misuse, 25.9 times more likely to result in major effect or death, 9.7 times more likely to require a visit to the ED, and 14.3 times more likely to result in hospital admission. Similar results were found for oxycodone IR when compared to Xtampza ER. Conclusions: This study is the first of its kind to synthesize clinical outcomes with opioid-related healthcare costs, suggesting that even when Xtampza ER is abused/misused, the rates of major effect/death, ED visits, and hospital admissions were significantly lower than those for other oxycodone-containing medications, resulting in relatively low downstream opioid-related healthcare costs.
Opioid prescribing among new users for non-cancer pain in the USA, Canada, UK, and Taiwan: A population-based cohort study

Meghna Jani,Nadyne Girard,David W. Bates,David L. Buckeridge,Therese Sheppard,Jack Li,Usman Iqbal,Shelly Vik,Colin Weaver,Judy Seidel,William G. Dixon,Robyn Tamblyn

DOI: https://doi.org/10.1371/journal.pmed.1003829

2021-11-01

PLoS Medicine

Abstract:Background The opioid epidemic in North America has been driven by an increase in the use and potency of prescription opioids, with ensuing excessive opioid-related deaths. Internationally, there are lower rates of opioid-related mortality, possibly because of differences in prescribing and health system policies. Our aim was to compare opioid prescribing rates in patients without cancer, across 5 centers in 4 countries. In addition, we evaluated differences in the type, strength, and starting dose of medication and whether these characteristics changed over time. Methods and findings We conducted a retrospective multicenter cohort study of adults who are new users of opioids without prior cancer. Electronic health records and administrative health records from Boston (United States), Quebec and Alberta (Canada), United Kingdom, and Taiwan were used to identify patients between 2006 and 2015. Standard dosages in morphine milligram equivalents (MMEs) were calculated according to The Centers for Disease Control and Prevention. Age- and sex-standardized opioid prescribing rates were calculated for each jurisdiction. Of the 2,542,890 patients included, 44,690 were from Boston (US), 1,420,136 Alberta, 26,871 Quebec (Canada), 1,012,939 UK, and 38,254 Taiwan. The highest standardized opioid prescribing rates in 2014 were observed in Alberta at 66/1,000 persons compared to 52, 51, and 18/1,000 in the UK, US, and Quebec, respectively. The median MME/day (IQR) at initiation was highest in Boston at 38 (20 to 45); followed by Quebec, 27 (18 to 43); Alberta, 23 (9 to 38); UK, 12 (7 to 20); and Taiwan, 8 (4 to 11). Oxycodone was the first prescribed opioid in 65% of patients in the US cohort compared to 14% in Quebec, 4% in Alberta, 0.1% in the UK, and none in Taiwan. One of the limitations was that data were not available from all centers for the entirety of the 10-year period. Conclusions In this study, we observed substantial differences in opioid prescribing practices for non-cancer pain between jurisdictions. The preference to start patients on higher MME/day and more potent opioids in North America may be a contributing cause to the opioid epidemic.

medicine, general & internal

A complication of fiberoptic intubation.

Digital obstructive arterial disease can be detected by laser Doppler measurements with high sensitivity and specificity.

RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system

Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)

Patterns of Routes of Administration and Drug Tampering for Nonmedical Opioid Consumption: Data Mining and Content Analysis of Reddit Discussions

Impact of COVID-19 Pandemic on Emergency Department Visits for Opioid Use Disorder Across University of California Health Centers

EPR studies of the cytochrome b-c 1 segment of the mitochondrial electron transfer system.

Serious Medical Outcomes due to Single Substance Opioid Exposures

Network Analysis and Visualisation of Opioid Prescribing Data

Reframing the Prevention Strategies of the Opioid Crisis: Focusing on Prescription Opioids, Fentanyl, and Heroin Epidemic

Large-scale Analysis of Opioid Poisoning Related Hospital Visits in New York State

Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review

Examining Racial/Ethnic Differences in Patterns of Opioid Prescribing: Results from an Urban Safety-Net Healthcare System

Evidence for the synthesis of thymosin alpha 1 by calf thymocytes and the production of this peptide by natural processing.

Progress, Challenges, and Prospects of Research on the Effect of Gene Polymorphisms on Adverse Reactions to Opioids

Monitoring the opioid epidemic via social media discussions

Evolution of an epidemic: Understanding the opioid epidemic in the United States and the impact of the COVID-19 pandemic on opioid-related mortality

Saving the planet, one handset at a time: designing low-power, low-bandwidth GPUs

Efficacy of opioids for traumatic pain in the emergency department: a systematic review and Bayesian network meta-analysis

Opioid-related clinical outcomes and associated healthcare costs following abuse/misuse of oxycodone formulations: A HEOR analysis from real-world data

Opioid prescribing among new users for non-cancer pain in the USA, Canada, UK, and Taiwan: A population-based cohort study